

Atty. Dkt. No. NB 2004.02 (060925-0402)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

H. Michael SHEPARD et al.

Title:

ENZYME CATALYZED THERAPEUTIC AGENTS

Appl. No.:

09/782,721

Filing Date:

2/12/2001

Examiner:

Crane, Lawrence E.

Art Unit:

1623

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

Many R. Zimmerman

Princed Name)

(Signature)

May 10, 2006

(Date of Deposit)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

05/15/2006 FFANAEIA 00000109 09782721

01 FC:1806

180.00 DP

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

<u>FEE</u>

A check in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 38706

Telephone: Facsimile:

(650) 251-1129

(650) 856-3710

Antoinette F. Konski

Attorney for Applicant

Registration No. 34,202

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Visite the Re	perwork Reduction Act	of 1995	5, no persons are re	equired to respond to a collection of info	rmation unless it contains a valid OMB control number.		
	Substitute for form	1449B/	PTO	Complete if Known			
	INECRMATION DIS	SCLO	SURE	Application Number	09/782,721		
MAY 1 5 200	STATEMENT BY A	PPLI	CANT	Filing Date	February 12, 2001		
				First Named Inventor	H. Michael SHEPARD		
	Late Submitted: M	iay 8,	2006	Group Art Unit	1623		
PAREMARY	se as many sheets	as ne	cessary)	Examiner Name	Crane, Lawrence E.		
Sheet	Se as many sheets 1	of	1	Attorney Docket Number	060925-0402		

				U.S. PATENT DOCUMENTS	}	•
_		U.S. Patent Document		No. of Detector or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	1	5,998,151		Johnston et al.	12-07-1999	

		U.S	. PATENT APPLICATION DOCUM	MENTS	
Cita	U.S. Patent Application Document		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
No. ¹	Serial Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	Cite No. ¹	Cite Docume	Cite No. 1 Serial Number Code (if	Cite No. 1 U.S. Patent Application Document Name of Patentee or Applicant of Cited Document Cited Document	Cite No. Serial Number Code (if Serial Number

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent D	Occument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		12-01			·			

NON PATENT LITERATURE DOCUMENTS								
Cite No. ¹	A U ITOM (DOOK MADAZINE INUMAL SENAL SYMDOSIUM CATALOO EU: LUAIE, DAUELA), VUIUME-188UE HUMBERAA,							
2	BALZARINI et al. "Increased sensitivity of thymidine kinase-deficient (TK*) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds" <i>Anticancer Research</i> (1986) 6 :1077-1084							
3	BALZARINI et al. "Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection" J. Acquired Immune Deficiency Syndromes and							
4	HUGHEY et al. "Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine" Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation (1993)							
	No. ¹ 2	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. BALZARINI et al. "Increased sensitivity of thymidine kinase-deficient (TK') tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds" Anticancer Research (1986) 6:1077-1084 BALZARINI et al. "Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection" J. Acquired Immune Deficiency Syndromes and Human Retrovirology (1998) 17:296-302 HUGHEY et al. "Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine" Novel						

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.